319 related articles for article (PubMed ID: 29471435)
1. Immune Infiltration in Invasive Lobular Breast Cancer.
Desmedt C; Salgado R; Fornili M; Pruneri G; Van den Eynden G; Zoppoli G; Rothé F; Buisseret L; Garaud S; Willard-Gallo K; Brown D; Bareche Y; Rouas G; Galant C; Bertucci F; Loi S; Viale G; Di Leo A; Green AR; Ellis IO; Rakha EA; Larsimont D; Biganzoli E; Sotiriou C
J Natl Cancer Inst; 2018 Jul; 110(7):768-776. PubMed ID: 29471435
[TBL] [Abstract][Full Text] [Related]
2. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
[TBL] [Abstract][Full Text] [Related]
4. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
5. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
6. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
[TBL] [Abstract][Full Text] [Related]
7. Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology.
Blohmer M; Zhu L; Atkinson JM; Beriwal S; Rodríguez-López JL; Rosenzweig M; Brufsky AM; Tseng G; Lucas PC; Lee AV; Oesterreich S; Jankowitz RC
Breast Cancer Res; 2020 Jun; 22(1):70. PubMed ID: 32586354
[TBL] [Abstract][Full Text] [Related]
8. Expression of DDR1 and DVL1 in invasive ductal and lobular breast carcinoma does not correlate with histological type, grade and hormone receptor status.
Ameli F; Rose IM; Masir N
Asian Pac J Cancer Prev; 2015; 16(6):2385-90. PubMed ID: 25824769
[TBL] [Abstract][Full Text] [Related]
9. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
[TBL] [Abstract][Full Text] [Related]
10. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
[TBL] [Abstract][Full Text] [Related]
11. [Accuracy of conservative treatment for infiltrating lobular breast cancer: a retrospective study of 217 infiltrating lobular carcinomas and 2155 infiltrating ductal carcinomas].
Paumier A; Sagan C; Campion L; Fiche M; Andrieux N; Dravet F; Pioud R; Classe JM
J Gynecol Obstet Biol Reprod (Paris); 2003 Oct; 32(6):529-34. PubMed ID: 14593298
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of metaplastic carcinoma of the breast (MCB)--a case controlled comparison study with infiltrating ductal carcinoma.
Lai HW; Tseng LM; Chang TW; Kuo YL; Hsieh CM; Chen ST; Kuo SJ; Su CC; Chen DR
Breast; 2013 Oct; 22(5):968-73. PubMed ID: 23787124
[TBL] [Abstract][Full Text] [Related]
13. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
[TBL] [Abstract][Full Text] [Related]
14. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
[TBL] [Abstract][Full Text] [Related]
16. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
Arpino G; Bardou VJ; Clark GM; Elledge RM
Breast Cancer Res; 2004; 6(3):R149-56. PubMed ID: 15084238
[TBL] [Abstract][Full Text] [Related]
17. Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival.
García-Fernández A; Lain JM; Chabrera C; García Font M; Fraile M; Barco I; Torras M; Reñe A; González S; González C; Piqueras M; Veloso E; Cirera L; Pessarrodona A; Giménez N
Breast J; 2015; 21(5):533-7. PubMed ID: 26190560
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population.
Lim ST; Yu JH; Park HK; Moon BI; Ko BK; Suh YJ
World J Surg Oncol; 2014 Mar; 12():56. PubMed ID: 24621330
[TBL] [Abstract][Full Text] [Related]
19. Axillary lymph node status and invasive lobular breast cancer : Analysis of the Clinical Tumor Register of the AGO Austria.
Danzinger S; Pöckl K; Kronawetter G; Pfeifer C; Behrendt S; Gscheidlinger P; Harrasser L; Mühlböck H; Dirschlmayer W; Schauer C; Reitsamer R; Uher H; Schönau K; Delmarko I; Singer CF
Wien Klin Wochenschr; 2023 Sep; 135(17-18):463-471. PubMed ID: 37010596
[TBL] [Abstract][Full Text] [Related]
20. Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers.
Romanska HM; Potemski P; Krakowska M; Mieszkowska M; Chaudhri S; Kordek R; Kubiak R; Speirs V; Hanby AM; Sadej R; Berditchevski F
Br J Cancer; 2015 Nov; 113(9):1350-7. PubMed ID: 26418423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
